| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-755
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 |
| filingDate |
2013-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2015-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2015527350-A |
| titleOfInvention |
Factor VIII liquid formulation |
| abstract |
The present invention provides a liquid aqueous formulation of coagulation factor VIII comprising a factor VIII molecule, a calcium salt at a concentration of greater than 10 mM, and a saccharide and / or polyol at a concentration of at least 100 mM and having a pH of 5.5 to 7.5. Target. The present invention is a method for optimizing a liquid formulation of coagulation factor VIII, comprising: (i) providing one or more liquid formulations comprising factor VIII to be tested; and (ii) Adding a protein denaturant to the liquid formulation and incubating the resulting solution for a predetermined period of time; and (iii) analyzing the incubated solution of (ii) for the presence of dissociated factor VIII; and iv) selecting one or more formulations having the desired low level of dissociated factor VIII. |
| priorityDate |
2012-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |